CA Patent

CA3233014A1 — Methods and compositions for avoiding off-target effects

Assigned to Regulus Therapeutics Inc · Expires 2023-04-13 · 3y expired

What this patent protects

Provided herein are compounds comprising modified oligonucleotides targeted to microRNAs, wherein the modified oligonucleotides are designed to avoid off-target effects.

USPTO Abstract

Provided herein are compounds comprising modified oligonucleotides targeted to microRNAs, wherein the modified oligonucleotides are designed to avoid off-target effects.

Drugs covered by this patent

Patent Metadata

Patent number
CA3233014A1
Jurisdiction
CA
Classification
—
Expires
2023-04-13
Drug substance claim
No
Drug product claim
No
Assignee
Regulus Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.